S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
NYSE:AVNS

Avanos Medical (AVNS) Stock Price, News & Analysis

$19.98
+0.08 (+0.40%)
(As of 03:45 PM ET)
Today's Range
$19.86
$20.13
50-Day Range
$18.43
$19.89
52-Week Range
$17.24
$31.31
Volume
90,934 shs
Average Volume
303,870 shs
Market Capitalization
$923.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00

Avanos Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
54.5% Upside
$31.00 Price Target
Short Interest
Bearish
2.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$152,960 Sold Last Quarter
Proj. Earnings Growth
33.33%
From $1.38 to $1.84 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.25 out of 5 stars

Medical Sector

343rd out of 938 stocks

Surgical Appliances & Supplies Industry

9th out of 17 stocks

AVNS stock logo

About Avanos Medical Stock (NYSE:AVNS)

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

AVNS Stock Price History

AVNS Stock News Headlines

Avanos Medical (NYSE:AVNS) Upgraded to Buy by StockNews.com
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AVNS Mar 2024 20.000 call
Avanos Medical Q4 2023 Earnings Preview
Avanos Medical, Inc. (AVNS)
New Strong Sell Stocks for January 9th
New Strong Sell Stocks for January 12th
New Strong Sell Stocks for January 16th
Avanos Medical Warns of 4Q, 2024 Sales Shortfalls
See More Headlines
Receive AVNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Fax
N/A
Employees
3,771
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.00
High Stock Price Target
$31.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+55.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-61,800,000.00
Pretax Margin
-1.17%

Debt

Sales & Book Value

Annual Sales
$673.30 million
Cash Flow
$2.06 per share
Book Value
$26.63 per share

Miscellaneous

Free Float
44,863,000
Market Cap
$918.92 million
Optionable
Optionable
Beta
0.95
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Joseph F. Woody (Age 58)
    CEO & Director
    Comp: $2.37M
  • Mr. Michael C. Greiner (Age 51)
    Senior VP, CFO & Chief Transformation Officer
    Comp: $940.45k
  • Ms. Mojirade James (Age 57)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $759.53k
  • Mr. Kerr W. Holbrook (Age 56)
    Senior VP, GM of Chronic Care & Chief Commercial Officer
    Comp: $716.87k
  • Mr. John Joseph Hurley
    Principal Accounting Officer & Controller
  • Mr. David Crawford
    VP of FP&A and Investor Relations and Treasurer
  • Ms. Michelle Scharfenberg
    Senior VP and Chief Ethics & Compliance Officer
  • Mr. Scott Galovan
    Vice President of Strategy & Corporate Development
  • John W. Cato
    Vice President of Human Resources
  • Mr. Lee Burnes
    Senior Vice President of Global R&D, Clinical and Medical Affairs

AVNS Stock Analysis - Frequently Asked Questions

Should I buy or sell Avanos Medical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AVNS shares.
View AVNS analyst ratings
or view top-rated stocks.

What is Avanos Medical's stock price target for 2024?

2 Wall Street analysts have issued 12-month price targets for Avanos Medical's shares. Their AVNS share price targets range from $31.00 to $31.00. On average, they predict the company's stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 54.5% from the stock's current price.
View analysts price targets for AVNS
or view top-rated stocks among Wall Street analysts.

How have AVNS shares performed in 2024?

Avanos Medical's stock was trading at $22.43 at the beginning of 2024. Since then, AVNS stock has decreased by 10.5% and is now trading at $20.07.
View the best growth stocks for 2024 here
.

Are investors shorting Avanos Medical?

Avanos Medical saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,340,000 shares, an increase of 6.3% from the February 29th total of 1,260,000 shares. Based on an average daily volume of 297,300 shares, the days-to-cover ratio is currently 4.5 days. Approximately 3.0% of the company's shares are sold short.
View Avanos Medical's Short Interest
.

When is Avanos Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our AVNS earnings forecast
.

How were Avanos Medical's earnings last quarter?

Avanos Medical, Inc. (NYSE:AVNS) announced its quarterly earnings results on Tuesday, February, 20th. The company reported $0.36 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by $0.01. The firm had revenue of $173.30 million for the quarter, compared to analysts' expectations of $170.43 million. Avanos Medical had a negative net margin of 8.76% and a positive trailing twelve-month return on equity of 4.25%. The firm's revenue for the quarter was down 4.6% compared to the same quarter last year. During the same period last year, the business earned $0.60 EPS.

What ETF holds Avanos Medical's stock?

Invesco S&P SmallCap Health Care ETF holds 119,434 shares of AVNS stock, representing 1.06% of its portfolio.

What guidance has Avanos Medical issued on next quarter's earnings?

Avanos Medical issued an update on its FY 2024 earnings guidance on Friday, February, 23rd. The company provided EPS guidance of 1.300-1.450 for the period. The company issued revenue guidance of $685.0 million-$705.0 million.

What is Joseph F. Woody's approval rating as Avanos Medical's CEO?

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), RTX (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.67%), Vanguard Group Inc. (11.73%), Dimensional Fund Advisors LP (6.15%), Westwood Holdings Group Inc. (4.63%), Paradice Investment Management LLC (3.56%) and Tributary Capital Management LLC (1.49%). Insiders that own company stock include Julie Ann Shimer, Michael Greiner and Patrick J Oleary.
View institutional ownership trends
.

How do I buy shares of Avanos Medical?

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AVNS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners